Category: Knowledge Base

With more than 20 years behind the pharmacy counter, Dr. Postell joins the Precision Telemed team to help guide compliance, quality, and patient safety across the company’s GLP-1 weight loss and hormone optimization programs.

TAMPA, FL — April 27, 2026 — Precision Telemed, the family-owned, doctor-led telemedicine platform known for its work in personalized weight loss, hormone therapy, and longevity care, is excited to welcome Danny Postell, PharmD, to its ownership group. A practicing pharmacist and longtime pharmacy owner, Dr. Postell joins the team at a moment when telehealth and compounded medications are evolving faster than ever, and when patients are asking more questions than ever about safety, quality, and the people behind their care.

His arrival marks a meaningful moment for the company. As a graduate of the University of Georgia College of Pharmacy and the owner of multiple pharmacies including Huff’s Pharmacy in Georgia, Dr. Postell brings the kind of experience you can only get by spending two decades behind the counter: filling prescriptions, talking to patients, working with physicians, and watching the industry change firsthand. That perspective, leadership at Precision Telemed says, is exactly what the company wanted to add at this stage of its growth.

“What drew me to Precision Telemed is how seriously they take patient care,” said Dr. Postell. “Telehealth has changed a lot of lives, but it only works when the clinical side and the pharmacy side are both rock solid. I’m looking forward to helping the team keep that bar high.”

A Pharmacist’s Eye on Patient Care

Anyone who’s spent time in an independent pharmacy knows the work is personal. You learn names. You notice when something’s off. You watch patients try medications, change doses, get better, hit setbacks, and start again. Dr. Postell has spent his career in that environment, and it’s shaped how he thinks about safety, compounding, and what good care actually looks like in practice.

In his role with Precision Telemed, he’ll work closely with the leadership team and the company’s pharmacy partners on the things that matter most behind the scenes: quality assurance, regulatory compliance, and keeping a close eye on FDA and state board guidance as it evolves. The goal isn’t just to meet today’s standards. It’s to stay ahead of where the industry is heading next.

Supporting the Programs Patients Rely On

Precision Telemed builds personalized treatment plans that pair clinician oversight with medications dispensed by trusted U.S. compounding pharmacies operating under 503A and 503B regulatory frameworks. Dr. Postell’s experience will support the company’s most-requested programs, including compounded semaglutide for medically guided weight management, compounded tirzepatide for patients exploring dual incretin therapy, and the microdose GLP-1 protocol for those who prefer a gentler, lower-dose approach to metabolic health.

“Danny is the kind of person you want in the room when big decisions are being made,” said Carlie Cannon-Rius, Owner and CEO of Precision Telemed. “He’s a pharmacist first, an owner second, and a problem-solver always. Having him in our ownership group means we get that lens on every decision, especially when it comes to safety and compliance. That’s exactly the partnership we wanted to build.”

Patients curious about Precision Telemed’s programs can head over to precisiontelemed.com to explore the available treatments, book a virtual consultation with a licensed provider, and learn more about how the team approaches care.

About Precision Telemed

Precision Telemed is a family-owned, doctor-led telemedicine company offering personalized care across weight loss, hormone optimization, and longevity. Patients work with licensed providers entirely online, receive pharmaceutical-grade compounded medications from trusted U.S. pharmacies, and get free customized nutrition and workout programs along the way. Pricing is transparent and all-inclusive, with no surprise fees. Learn more at precisiontelemed.com or visit the About Us page to read more about the team and the company’s approach.

Media Contact

Precision Telemed

3030 N Rocky Point Drive W, Suite 150

Tampa, FL 33607

Email: [email protected]

Call: (877) 745-4115

Text: (877) 745-4115

Website: https://precisiontelemed.com/contact-us/

Disclaimer

Precision Telemed offers only compounded medications, which are made in State Board of Pharmacy licensed sterile compounding pharmacies, or FDA-licensed 503(b) Outsourcing Facilities. These facilities are strictly regulated. The products themselves are not FDA-approved due to the provider’s prescriptions being customized to the patient’s needs. Compounded medications differ from FDA-approved products in factors such as strength, dose, and route of administration, which makes direct comparison to FDA-approved products difficult. All compounded drugs prescribed are based on a licensed healthcare provider’s medical judgment from a telehealth encounter that includes medical history.

Precision Health Digital LLC is a patient management platform that works with Doctors Now PC, a group of independent physicians and practitioners. Precision Telemed does not provide medical services, and payment does not guarantee the writing of a prescription. Doctors Now PC provides medical services using the Precision Health Digital platform. The information in this release is for informational purposes and is not a substitute for professional medical advice, diagnosis, or treatment.

If the scale has stopped moving on semaglutide, or never really started, you are not alone and you are not failing the medication. Plateaus and slow starts on this class of drug are common, and almost all of them have an explainable cause that a provider can help address. 

The point of this article is not to make you feel bad about anything you might be doing wrong. It is to walk through the most common reasons the scale stalls so you can have a more useful conversation at your next visit.

If you feel your treatment isn’t working, speak with your provider before making any changes. Protocol adjustments can often help significantly.

It Is Almost Always Addressable

Before getting into specific causes, hold onto this: weight loss on semaglutide is rarely a linear downward line. The scale moves in waves. Patients who track daily weights often see fluctuations that obscure the longer trend. 

Patients who weigh once a week or once every two weeks usually see the trend more clearly, and even those weeks can include stretches of nothing happening on the surface even when fat loss is occurring underneath (water retention, muscle changes, hormonal cycles, and digestive variations all influence the number on the scale day to day).

What that means is that two or three weeks of no scale movement is rarely a “real” plateau. Six to eight weeks without movement, or a clear stop after months of progress, is when it makes sense to dig into causes.

Where You Are in the Dose Titration

Semaglutide for weight management starts at 0.25 mg per week and steps up gradually to a maintenance dose of 2.4 mg over about 17 weeks. The lower doses are designed to introduce the medication slowly so the body has time to adjust to the gastrointestinal effects. The therapeutic effect on appetite and weight builds gradually as the dose climbs.

That schedule has a practical implication. If you are still in your first 8 to 12 weeks at low doses, you may not yet be at a dose that produces noticeable appetite suppression for your body. Some patients respond strongly at 0.5 mg or 1.0 mg. Others need to reach 1.7 mg or 2.4 mg before the effect becomes meaningful. Individual variability is real and expected.

If your provider has held you at a lower dose because of side effects, that is a clinical decision worth revisiting at your next visit. Many patients who initially struggle with side effects can tolerate a slow re-escalation once their body has adjusted, and reaching a more therapeutic dose often unlocks progress.

Your Body Adapts, and That Is Normal

Once you are at a therapeutic dose, the body still has its own physiology to contend with. Metabolic adaptation is well documented in weight loss across every method studied, including bariatric surgery, behavioral interventions, and now incretin-based medications.

As fat stores decrease, the body responds by lowering resting metabolic rate, increasing appetite signals, and conserving energy more efficiently. This is not a flaw in your willpower; it is your body trying to defend its prior weight set point.

The good news is that the STEP 4 trial published in JAMA showed that patients who continued weekly semaglutide kept losing weight gradually, with the trend reaching its plateau around week 60 to 68 and total reduction reaching about 17.4% over the trial. 

Patients who stopped treatment regained weight. The medication is doing real work in keeping appetite signals quieter than they would otherwise be, and that work continues even when the rate of loss slows.

A plateau after months of progress is often the body recalibrating. A provider may recommend a dose adjustment, a check on protocol consistency, or in some cases the addition of complementary therapies that support metabolic function. Some patients explore NAD+ as part of a broader metabolic support strategy alongside their GLP-1 medication, particularly when energy and overall metabolic resilience feel diminished.

Diet Creep Is Real, and Not a Moral Failing

This is the cause patients are most reluctant to consider, and the one most worth approaching without judgment. Caloric intake creeps up over time on most weight loss approaches, often without the patient noticing. Semaglutide reduces appetite, but it does not eliminate appetite, and as side effects fade and the body adapts, eating patterns can drift. 

A few extra bites here, a return to eating out more often, larger portions of items that feel “safe” because the medication used to help control them.

The fix is not a stricter diet or self-flagellation. A short food log over a week or two often makes patterns visible. Many patients find their providers can help them recalibrate based on what is actually happening, with no shame attached.

Timing, Consistency, and Practical Variables

Some plateaus come from variables that have nothing to do with willpower. Inconsistent injection timing (skipping a week or pushing the dose later) reduces blood levels of the medication and the corresponding appetite effect. 

Storage issues that affect potency are uncommon but possible. Switching brands or sources mid-protocol can change actual delivered dose. Hydration affects how the medication is absorbed and how the body responds.

The practical version of this is simple. Same day each week, consistent storage, no skipped doses unless instructed by a provider. If your routine has slipped (which happens to virtually everyone over months of treatment), a reset on consistency is sometimes enough by itself to break a plateau.

Underlying Conditions Worth Ruling Out

Not every plateau is about medication or your habits. A handful of underlying conditions can blunt response or cause weight retention even when everything else looks right.

Thyroid function is the first one to consider. Untreated or undertreated hypothyroidism makes weight loss substantially harder regardless of medication. A simple TSH and free T4 panel rules it in or out. 

Insulin resistance and metabolic syndrome can also blunt the effect of GLP-1 medications, and some patients benefit from a complementary approach to insulin sensitivity. Polycystic ovary syndrome, sleep apnea, certain medications (some antidepressants, beta-blockers, corticosteroids), and chronic stress with elevated cortisol can all contribute.

For some patients, a more comprehensive peptide therapy approach to overall health optimization addresses underlying issues that GLP-1 medications alone cannot. 

In other cases, an adjunctive peptide like sermorelin can support the body composition side of weight loss by helping preserve lean mass during caloric restriction. These are individualized decisions that come out of a real conversation with a provider who has reviewed your full picture.

What Not to Do

A few things to avoid if the scale has stalled. Do not stop the medication abruptly. The data is consistent that stopping leads to weight regain, often quickly. Do not double up doses to “catch up” or push past a plateau on your own. Do not assume the medication is “broken” or “stopped working”; that framing is rarely accurate and tends to lead to decisions that make things worse.

Almost always, a plateau is a signal that something in the protocol, the dose, the lifestyle, or the underlying physiology deserves a fresh look. That look is what a provider visit is for.

Bring This to Your Next Visit

A telehealth follow-up is the most direct path to figuring out what is going on. Your provider can review where you are in the dose schedule, screen for underlying issues, talk through any lifestyle or timing factors, and discuss whether a protocol adjustment makes sense. In a single visit, most patients can identify the cause and leave with a concrete plan. Schedule an appointment today.

If your weight loss has stalled, please talk to your provider before stopping or changing your medication. Plateaus are addressable, but the right response depends on your individual situation. This article is for informational purposes only and does not constitute medical advice.

Semaglutide and tirzepatide both quiet appetite, slow stomach emptying, and improve how the body handles glucose after meals. The biology that gets them there is not the same. 

One activates a single hormone receptor; the other activates two. That difference cascades into distinct dosing schedules, slightly different side effect profiles, different brand-name products, and different bodies of clinical evidence supporting each one.

This article is for general comparative education and does not constitute medical advice. Whether semaglutide or tirzepatide is appropriate for an individual depends on their full clinical picture and should be determined with a licensed prescribing provider.

Same Drug Class, Different Molecules

Both medications belong to a broader category called incretin-based therapies. Incretins are gut hormones released after eating that signal the pancreas to release insulin, slow gastric motility, and reduce hunger. Two of the main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Semaglutide is a GLP-1 receptor agonist. The molecule is structurally similar to native GLP-1 with chemical modifications that resist breakdown, allowing for once-weekly dosing.

Tirzepatide is a dual incretin receptor agonist. It activates both the GIP receptor and the GLP-1 receptor. The molecule is a 39-amino-acid peptide engineered to bind both targets, though not equally. 

Pharmacology studies have characterized tirzepatide as an “imbalanced” agonist that favors GIP receptor activity, with a binding pattern at the GLP-1 receptor that differs from native GLP-1 in subtle but clinically meaningful ways.

According to a recent review in The Lancet on next-generation incretin-based medications, tirzepatide is currently the only dual agonist specifically targeting GIP and GLP-1 receptors that has been approved for both type 2 diabetes and obesity. Whether the GIP component drives the additional weight loss seen with tirzepatide compared to GLP-1 monotherapy, or whether other mechanisms contribute, is still an active area of investigation.

Brand Names and Indications

This is where most of the practical confusion comes from. Each active ingredient is sold under multiple brand names depending on the indication.

Semaglutide is marketed as Ozempic for adults with type 2 diabetes, as Wegovy for chronic weight management in adults with obesity or overweight with comorbidities, and as Rybelsus in an oral tablet form for type 2 diabetes. The injectable forms are once-weekly. The oral form is daily and requires strict fasting protocols for proper absorption.

Tirzepatide is marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management as well as moderate-to-severe obstructive sleep apnea in adults with obesity (this last indication was added in December 2024). Both are once-weekly subcutaneous injections.

The active ingredient does not change between the brand names of a given drug. What changes is the labeled indication, which affects insurance coverage and prescribing context. 

For patients exploring compounded semaglutide as part of a structured medical program, the same molecule logic applies, though the regulatory framework around compounded medications is different from the FDA-approved branded products.

Dose Titration Schedules

Both medications start at low doses and escalate gradually to minimize gastrointestinal side effects, which tend to concentrate during the dose-escalation phase rather than after a patient reaches steady state.

Semaglutide for weight management starts at 0.25 mg per week and escalates over 17 weeks to reach the maintenance dose of 2.4 mg. Each step requires a minimum of four weeks before moving to the next.

Tirzepatide also starts at 2.5 mg per week and escalates over approximately 21 weeks to reach the maximum dose of 15 mg, again with at least four weeks between dose increases. Most patients do not need to reach the maximum dose to see meaningful results, and many maintain their treatment at intermediate doses indefinitely.

The slower titration of tirzepatide reflects both the wider dosing range and the practical reality that patients tolerate the higher steps better when the climb is gradual. 

Some clinical programs use microdosed protocols that hold patients at lower-than-standard doses to balance benefit and side effect burden, particularly during long-term maintenance.

Side Effect Profiles

The two medications share most of their adverse event profile, with gastrointestinal effects leading the list. There are real but relatively subtle differences in how those effects tend to present.

Patients on semaglutide more commonly report nausea and constipation. Patients on tirzepatide more commonly report diarrhea, with somewhat less nausea on average. In the head-to-head trial that compared the two, gastrointestinal events serious enough to cause treatment discontinuation occurred more often with semaglutide than with tirzepatide.

Both medications carry the same FDA boxed warning regarding thyroid C-cell tumors based on rodent data. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use either drug. Both can also cause pancreatitis, gallbladder issues, hypoglycemia (particularly when combined with insulin or sulfonylureas), and kidney problems related to severe dehydration from prolonged vomiting or diarrhea.

There is also a related concern that affects patients on either medication: significant weight loss can come with loss of lean muscle mass alongside fat mass. Some clinical programs combine GLP-1 therapy with peptide protocols aimed at preserving muscle mass during GLP-1 treatment to address this.

Cardiovascular and Long-Term Outcomes

This is one area where the evidence base for the two drugs differs in meaningful ways. Semaglutide has been studied extensively for cardiovascular outcomes, and the SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events in adults with obesity and established cardiovascular disease but without diabetes. That data underpins a separate FDA-approved indication for cardiovascular risk reduction in this population.

Tirzepatide has cardiovascular outcomes trials in progress, but a fully reported head-to-head cardiovascular outcome trial result is not yet available. Early data from completed obesity trials suggests favorable directional effects on cardiometabolic risk factors, but the high-quality evidence specific to major cardiovascular events is still maturing.

For patients whose decision is driven primarily by cardiovascular risk reduction rather than weight loss alone, that asymmetry in evidence matters and is worth discussing explicitly with the prescribing provider.

Cost and Access Realities

Branded Wegovy, Ozempic, Mounjaro, and Zepbound can be expensive without insurance coverage, and coverage for weight management indications remains inconsistent across plans. Manufacturers have introduced direct-pay programs (LillyDirect for Zepbound, NovoCare for Wegovy) that reduce out-of-pocket costs for patients without coverage.

Compounded versions of these molecules previously addressed cost gaps during the period when both drugs were on the FDA’s drug shortage list. Both have since been removed from that list, and the regulatory environment around compounded GLP-1 medications has tightened significantly. Today, compounded versions exist within narrower legal parameters than they did in 2023 or early 2024.

How Providers Choose Between Them

The choice rarely comes down to a single factor. Providers typically weigh the patient’s primary clinical goal (glycemic control, weight reduction, OSA management, cardiovascular risk reduction), prior response to GLP-1 medications if any, side effect tolerance, cost reality, insurance coverage, and any contraindications.

Patients with a strong preference for one medication over the other based on what a friend or family member is taking should know that individual response varies considerably. 

Some patients tolerate semaglutide better; others tolerate tirzepatide better. Some respond well to both; some respond modestly to both. The data from clinical trials reflects averages, and an average is not a forecast for any one person.

Schedule a Conversation With a Provider Who Prescribes Both

If you are still weighing semaglutide and tirzepatide for your situation, the most useful next step is a conversation with a clinician who can review your health history, lab work, and goals before recommending one over the other. 

Precision Telemed offers a free 15-minute introductory call where a provider can walk through both options with you, with no obligation to start treatment. Schedule an appointment today!

This article is for informational purposes only and does not constitute medical advice. Both semaglutide and tirzepatide are prescription medications. Individual results vary. Consult a licensed healthcare provider before starting, stopping, or changing any prescription medication.

The question gets asked a lot, and the framing already tells you something. Testosterone is not a weight loss medication. It is a hormone that, in men with documented deficiency, can change body composition in ways that include some fat loss and some lean mass gain. 

Those are real effects, supported by clinical evidence, but they are not the same thing as taking a drug to lose weight. Sorting that distinction out is what this article is for.

Testosterone therapy is a prescription treatment indicated for clinically diagnosed hormonal deficiency. It is not a weight-loss medication. Discuss your hormonal health with a licensed provider.

What “Weight Loss” Actually Means in This Context

When clinicians talk about testosterone affecting weight, they almost always mean changes in body composition. That is a different measure than what shows up on a bathroom scale. 

Body composition refers to the proportion of fat mass to lean mass (muscle, bone, organs). A man on testosterone replacement therapy might gain a few pounds of muscle while losing a few pounds of fat, and the scale could barely move. That is not a treatment failure. It is the physiology working.

This matters because patients searching for a “weight loss” effect from testosterone are often hoping for the kind of dramatic scale change associated with GLP-1 medications. That is not what testosterone does, and framing it that way sets up the wrong expectation.

What the Evidence Shows in Men

The strongest evidence base is in men with clinically diagnosed hypogonadism, meaning consistently low testosterone levels confirmed on at least two morning blood tests, accompanied by symptoms.

According to the Endocrine Society Clinical Practice Guideline on testosterone therapy, testosterone therapy in healthy men with hypogonadism increases fat-free mass and muscle strength while reducing fat mass. The effects are modest in absolute terms. Meta-analyses generally report increases in lean mass on the order of 1 to 3 kg and reductions in fat mass that are smaller and less consistent across studies.

In men with obesity and confirmed testosterone deficiency, the picture can look more favorable. Some longer-term observational data has reported meaningful reductions in body weight, BMI, and waist circumference over years of treatment. The honest read is that these benefits appear strongest when testosterone deficiency is actually present, treatment is sustained, and lifestyle changes are also in place.

What testosterone therapy does not appear to do is produce weight loss in men whose testosterone levels are normal. The Endocrine Society explicitly recommends against prescribing testosterone to men without confirmed deficiency, and that includes men who are simply hoping for body composition or weight benefits.

What the Evidence Shows in Women

Women produce small amounts of testosterone, and it plays a role in mood, libido, energy, and aspects of musculoskeletal health. Its role in body composition or weight regulation, however, is far less established than in men.

There is some evidence that supraphysiologic doses of androgens influence body composition in women. That data does not justify using testosterone as a weight loss tool. 

The clinical use of testosterone in women is largely focused on hypoactive sexual desire disorder and certain perimenopausal or postmenopausal symptoms, and even those uses remain off-label in most countries. The international consensus position from leading endocrine societies has been clear that testosterone therapy in women is not indicated for weight management.

For women asking whether testosterone could help with weight loss, the honest clinical answer is that the evidence does not support that use, and the safety profile (acne, voice changes, hair changes at higher doses) does not justify it as an off-label experiment.

Why It Works (When It Works) in Men With Deficiency

Testosterone influences body composition through several pathways. It supports protein synthesis in skeletal muscle, modulates the differentiation of stem cells away from fat storage and toward muscle, and appears to affect resting metabolic rate. Men with untreated hypogonadism often experience a gradual loss of muscle mass and an accumulation of visceral fat, particularly with age.

Restoring testosterone to the normal physiological range can partially reverse those changes. The effect is gradual, taking months to fully appear, and it depends on continued treatment. Stop the therapy, and the changes tend to reverse over time.

There is also a behavioral component that is harder to measure. Men with treated testosterone deficiency often report more energy, better mood, and improved motivation for exercise. Whether the body composition changes seen in clinical trials are driven mostly by the hormone or partly by these secondary effects is an open question. Probably both.

What Testosterone Therapy Is Actually For

The clinical indication for testosterone replacement is treating hypogonadism, which means restoring physiological levels in men with documented deficiency and consistent symptoms. The goals are to relieve those symptoms (low libido, fatigue, depressed mood, loss of muscle mass, decreased bone density, anemia in some cases) and to support overall metabolic and skeletal health.

Body composition improvement is a real and welcome secondary benefit when it occurs, but it is not the indication. Patients who pursue testosterone therapy through a structured medical program typically do so because they have symptoms of deficiency that have affected their quality of life, and the diagnosis is confirmed before treatment begins.

The Diagnosis Has to Come First

This is the part that often gets skipped in online discussions. The clinical guidelines are explicit: testosterone therapy is appropriate when a patient has both symptoms of androgen deficiency and consistently low total testosterone confirmed on two separate morning blood tests, ideally combined with assessment of free testosterone, LH, FSH, prolactin, and other relevant markers.

A complete evaluation also typically includes hematocrit, PSA (in men over a certain age), lipid panel, and other markers that establish baseline safety parameters. This is the kind of workup that gets done as part of comprehensive lab work for hormone optimization, not estimated from symptoms alone.

Without that diagnostic step, treating “low testosterone” based on symptoms or self-perception risks two things at once: missing other causes of those symptoms (thyroid issues, sleep apnea, depression, anemia) and exposing a patient to a prescription hormone that does not have a clear indication for them.

Side Effects and Risks Worth Knowing

Testosterone therapy is generally well tolerated when prescribed and monitored appropriately, but it has a real side effect profile that should be part of the decision. 

Possible effects include increased red blood cell count (which sometimes requires therapeutic phlebotomy), acne, fluid retention, sleep apnea exacerbation, suppression of natural testosterone production, and reduced fertility. 

The cardiovascular safety question has been studied extensively, with the FDA-mandated TRAVERSE trial published in NEJM finding no significant increase in major adverse cardiovascular events compared to placebo in men with hypogonadism.

For patients also interested in growth hormone axis support, sermorelin therapy is sometimes used alongside or instead of testosterone in appropriately selected cases. Whether that combination makes sense for a given patient depends on their full hormonal profile and goals.

The Honest Bottom Line

If you are a man with confirmed testosterone deficiency, treatment can support meaningful improvements in body composition over time, alongside the symptom relief that is the actual indication. 

Some of that change may show up on the scale; much of it shows up in waist size, body composition scans, or how clothes fit. If you are a woman, or a man with normal testosterone levels, testosterone therapy is not an evidence-based path to weight loss, and the risks generally outweigh whatever modest body composition effect might occur.

Anyone weighing this decision benefits from a full hormonal evaluation rather than a guess.

Schedule a Comprehensive Hormonal Evaluation

If you are curious about your hormonal health (whether the question is really about energy, libido, body composition, or general well-being), the most useful starting point is a complete panel review with a provider who can interpret the results in the context of your symptoms and history. 

Precision Telemed’s evaluation includes a thorough lab review and an honest conversation about whether testosterone therapy is the right answer for your specific situation, or whether something else should come first. Book your initial consultation!

This article is for informational purposes only and does not constitute medical advice. Testosterone is a prescription medication. Diagnosis, treatment, and monitoring should be performed by a licensed healthcare provider. Individual results vary.

When people hear about dramatic weight loss results online, the conversation usually becomes “Which is better: Mounjaro or Ozempic?”

It’s not that simple, there’s more to it than just a straightforward answer.

These medications aren’t interchangeable, and the comparison goes beyond brand names. To understand which one may lead to better weight loss, it helps to look at what each drug actually does, how the clinical trials compare, and why two people can have completely different experiences on the same medication.

The data does suggest that Mounjaro may produce greater average weight loss in many patients. Still, trial results only tell part of the story. Your outcome can depend on factors like dosage, consistency, side effects, lifestyle habits, underlying health conditions, and how your body responds to treatment overall.

This article is for informational purposes only and does not constitute medical advice. Any decision about treatment should be made with a licensed healthcare provider after an individualized medical evaluation.

The Brands and What They Actually Are

Mounjaro is the FDA-approved brand name for tirzepatide, indicated for type 2 diabetes. Ozempic is the brand name for semaglutide, also indicated for type 2 diabetes. 

When people ask whether one is better for weight loss, they are usually thinking of two related products: Zepbound (tirzepatide for chronic weight management) and Wegovy (semaglutide for chronic weight management). Both Zepbound and Wegovy carry FDA approval specifically for weight loss in adults who meet defined BMI criteria.

This distinction matters because prescribing the diabetes-labeled brand for weight loss is technically off-label. The clinical data on weight loss outcomes was generated under the obesity indications, not the diabetes ones. The active ingredients are identical, but the labeled use is not.

How They Work in the Body

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide 1, a hormone the gut releases after eating, which slows stomach emptying, reduces appetite, improves insulin response, and lowers blood glucose.

Tirzepatide takes that idea further. It activates two receptors instead of one: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP plays a separate role in fat metabolism and energy balance. 

Activating both pathways in tandem appears to produce additive effects on appetite suppression and metabolic function, though the precise mechanisms are still being mapped. Our overview of compounded tirzepatide as a dual-action peptide walks through this in more detail.

Both medications were originally developed for type 2 diabetes management, where they showed glycemic improvements that exceeded older drug classes. 

The weight loss observed in those diabetes trials was significant enough that researchers ran dedicated obesity programs (the STEP trials for semaglutide and the SURMOUNT trials for tirzepatide), which produced the data that supported the FDA approvals of Wegovy and Zepbound for chronic weight management.

The First Direct Comparison

Before 2025, comparing tirzepatide and semaglutide meant comparing separate trials with different patient groups, different protocols, and different endpoints. Indirect comparisons can be useful, but they always carry caveats.

That changed with the SURMOUNT-5 trial published in the New England Journal of Medicine. The study randomized 751 adults with obesity or overweight (with at least one weight-related comorbidity, and without type 2 diabetes) to receive either tirzepatide at the maximum tolerated dose (10 or 15 mg) or semaglutide at the maximum tolerated dose (1.7 or 2.4 mg) for 72 weeks.

At 72 weeks, the tirzepatide group lost an average of 20.2% of body weight. The semaglutide group lost an average of 13.7%. 

Tirzepatide also outperformed semaglutide on every key secondary endpoint, including the percentage of participants reaching weight reductions of at least 10%, 15%, 20%, and 25%.

That is, by any measure, a meaningful difference. 

Why the Numbers Don’t Settle the Question

What an average tells you is not what your individual outcome will be. Trials measure means and medians; people live as individuals.

A few things are worth holding in mind. The 13.7% mean weight loss seen with semaglutide is itself a remarkable result clinically, well above what any non-surgical intervention produced before this drug class arrived. 

For most patients with obesity, that level of weight reduction translates into significant improvements in cardiometabolic markers, sleep apnea, joint pain, and other comorbidities. Individual response also varies in ways that cannot be predicted in advance: some patients respond better to semaglutide than to tirzepatide for reasons that are not fully understood. 

And tolerability matters as much as efficacy. A medication with slightly higher trial-average weight loss is not the better choice if a patient cannot tolerate it consistently enough to reach a therapeutic dose.

There is also a practical reality. The medications need to be available, affordable, and sustainable for the patient over the long term. None of those factors appear in the SURMOUNT-5 weight curve.

One additional disclosure worth noting: SURMOUNT-5 was funded by Eli Lilly, the manufacturer of tirzepatide. That is a routine conflict of interest disclosure, not a reason to discount the result. Phase 3 trials are run under strict protocols, and NEJM peer review is substantial. But it is the kind of context an honest reading of the data should include.

Side Effect Profiles

The two drugs share most of their adverse event profile, with gastrointestinal effects leading the list during dose escalation. There are some real differences in how those effects tend to present.

Patients on semaglutide more commonly report nausea and constipation. Patients on tirzepatide more commonly report diarrhea, with somewhat less nausea on average. 

In SURMOUNT-5, gastrointestinal adverse events leading to treatment discontinuation occurred at 5.6% with semaglutide and 2.7% with tirzepatide. Both drugs become significantly easier to tolerate once a patient is past the dose-escalation phase and at steady state.

Both medications carry the same FDA boxed warning regarding thyroid C-cell tumors, based on rodent studies. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 should not use either medication.

Cost, Coverage, and Real-World Access

Branded Zepbound and Wegovy can be expensive without insurance coverage, and coverage for weight management is inconsistent across plans. 

Some patients access these medications through compounding pharmacies, though the regulatory and supply environment has shifted considerably since the FDA removed both from the official drug shortage list. Compounded options remain legal in specific clinical circumstances, but the rules are now narrower.

For patients exploring their options, our prescribing and safety information pageexplains how Precision Telemed approaches sourcing, dosing, and monitoring across both medications. 

Another option some providers now use is a microdosed dual GIP/GLP-1 protocol, which aims to reduce side effect burden and cost while maintaining clinical effect. These are off-label approaches and should only be initiated under provider supervision.

So Which One Is Right for You?

If the question is which medication produced more weight loss in the only direct head-to-head trial published so far, the answer is tirzepatide. If the question is which medication is right for an individual person, the data alone does not answer that. It points to a reasonable starting place, but the right protocol depends on health history, prior response to other medications, side effect tolerance, cost reality, comorbidities, and lifestyle.

A provider who reviews your full clinical picture is the only person who can give you a meaningful recommendation. That is not a deflection. It is just accurate.

Talk to a Provider Who Knows Both Medications

If you are weighing these options, the most useful next step is a conversation with a clinician who prescribes both and can speak to how the choice plays out in real practice. 

A 15-minute consultation with the Precision Telemed team can put the trial data in the context of your own health, lab work, and goals, with no cost or obligation. Book your initial visit!

This article is for informational purposes only and does not constitute medical advice. Individual results vary. Consult a licensed healthcare provider before starting, stopping, or changing any prescription medication.

If you’ve searched for weight loss medications recently, you’ve probably noticed that Zepbound and Wegovy and Ozempic all seem to get mentioned in the same breath. 

They’re covered by the same news outlets, prescribed for the same conditions, and discussed in the same online communities. It’s completely understandable to assume they’re versions of the same drug, or that Zepbound is just a brand name for semaglutide.

It isn’t. Zepbound contains tirzepatide, which is a different molecule from semaglutide in meaningful ways. Both are effective treatments for obesity. Both work through related but distinct mechanisms. 

And the choice between them isn’t as simple as picking one brand over another; it’s a pharmacological question that’s worth understanding before you have that conversation with a provider.

Drug selection should be based on your provider’s assessment of your individual health needs.

Zepbound Does Not Contain Semaglutide

This is the short answer to the question in the title: no, Zepbound is not a semaglutide product.

Zepbound is the brand name for tirzepatide, approved by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Tirzepatide is also sold under the brand name Mounjaro, which carries the same approval for type 2 diabetes.

Semaglutide is a completely separate molecule, sold under the brand names Wegovy (for weight management) and Ozempic (for type 2 diabetes). The two drugs are not interchangeable, do not contain the same active ingredient, and are not manufactured by the same company. Tirzepatide comes from Eli Lilly. Semaglutide comes from Novo Nordisk.

The confusion is understandable partly because both medications belong to a broader drug category that includes GLP-1 receptor agonists. But belonging to the same category doesn’t mean they’re the same drug, any more than two different antibiotics being “antibiotics” means they work identically.

What Semaglutide Is

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking GLP-1, a hormone your gut releases after eating, which signals the brain to reduce hunger, slows the rate at which the stomach empties, and improves insulin secretion in response to blood sugar.

The result is that people eat less, feel fuller sooner, and often experience significant weight loss over months of treatment. In the STEP-1 trial, once-weekly semaglutide at 2.4mg produced a mean body weight reduction of about 15% at 68 weeks.

Semaglutide is delivered as a once-weekly subcutaneous injection and has been available in its approved obesity dose since 2021. Compounded versions have been widely used during periods of branded shortage.

You can read more about how compounded semaglutide works within a medically supervised program at Precision Telemed.

What Tirzepatide Is

Tirzepatide is a dual agonist, meaning it activates two different receptors rather than one. It targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously.

GIP is a gut hormone that works alongside GLP-1 in regulating insulin secretion, energy metabolism, and fat storage. GIP receptors are found not just in the gut and pancreas but in adipose tissue and the brain, which is why activating both pathways together produces metabolic effects that go beyond what GLP-1 agonism alone achieves.

This dual mechanism is what makes tirzepatide pharmacologically distinct from semaglutide. It’s not simply a stronger version of the same approach; it’s a different approach that happens to overlap with semaglutide on the GLP-1 side. Our post on compounded tirzepatide as a dual-action peptide goes into more depth on the mechanistic differences.

How Their Mechanisms Translate in Practice

The practical difference between GLP-1 only (semaglutide) and dual GLP-1/GIP (tirzepatide) shows up in the clinical data.

The SURMOUNT-5 trial, published in the New England Journal of Medicine in May 2025, was the first head-to-head comparison between tirzepatide and semaglutide for weight loss in adults with obesity without diabetes. In 751 participants randomized to receive the maximum tolerated dose of either medication over 72 weeks, tirzepatide produced a mean body weight reduction of 20.2%, compared to 13.7% for semaglutide. Tirzepatide also produced greater improvements in waist circumference and several cardiometabolic markers.

Gastrointestinal side effects leading to treatment discontinuation were reported more frequently with semaglutide (5.6%) than with tirzepatide (2.7%), which researchers partly attributed to GIP’s counterregulatory effects on GLP-1-driven nausea pathways.

These are meaningful clinical differences. They’re also not the only factors that determine which medication is right for an individual patient.

Why Neither Drug Is Automatically Better for Everyone

Head-to-head data showing one drug outperformed another at the group level doesn’t mean every person responds the same way. Individual response to these medications varies considerably, for reasons that aren’t fully predictable before treatment starts.

Some people achieve excellent results on semaglutide and tolerate it well. Others respond more strongly to tirzepatide’s dual mechanism, or find that the tolerability profile suits them better. Access, cost, insurance coverage, and individual health factors all play into which treatment makes the most sense in a given situation.

There are also clinical contexts where one medication may be preferred over the other. A patient’s metabolic profile, history of GI issues, blood sugar patterns, existing medications, and specific health goals all factor into a well-reasoned prescribing decision. Someone with a history of significant nausea on GLP-1 medications, for instance, might benefit from the evidence suggesting tirzepatide’s GIP component moderates some of those GI effects. Someone already doing well on semaglutide has little reason to switch. These are nuanced, individualized calls. That conversation belongs in a clinical visit, not a product comparison page.

The compounded versions of both drugs, available through programs like the one at Precision Telemed, offer an accessible path to treatment for many patients who face cost or availability barriers with branded versions.

Clearing Up the Brand Confusion

Brand names in this drug category can be genuinely confusing. Multiple products, two different active ingredients, two different companies, and overlapping use cases across diabetes and obesity make it easy for even attentive patients to mix things up. Here’s a plain-language overview of which drug is which.

Semaglutide products:

• Wegovy (semaglutide 2.4mg, FDA-approved for weight management)
• Ozempic (semaglutide 0.5mg to 2mg, FDA-approved for type 2 diabetes)
• Rybelsus (oral semaglutide, FDA-approved for type 2 diabetes)

Tirzepatide products:

• Zepbound (tirzepatide, FDA-approved for weight management)
• Mounjaro (tirzepatide, FDA-approved for type 2 diabetes)

The on-label weight management approvals for both drug classes are for the higher-dose versions: Wegovy for semaglutide and Zepbound for tirzepatide. Both Ozempic and Mounjaro are formally diabetes treatments, though both are commonly discussed in the context of weight loss.

Understanding which active molecule is in which product is the first step toward having a more informed conversation with your prescribing provider about what might be the right fit for you.

If you’re trying to sort out which of these two drug classes makes more sense for your situation, a Precision Telemed provider can walk through your health history, metabolic markers, and goals with you and help you make a well-informed decision. Get started with a consultation!

Drug selection should be based on your provider’s assessment of your individual health needs. This content is for informational purposes only and does not constitute medical advice.

Losing a significant amount of weight is genuinely good for your health. It reduces blood pressure, improves insulin sensitivity, takes stress off joints, and extends life. But for many people, the body that shows up on the other side doesn’t look quite the way they imagined, and loose skin is one of the more frustrating parts of that gap between expectation and reality.

The good news is that several evidence-based strategies can meaningfully influence how your skin responds to weight loss. The less satisfying news is that none of them carry guarantees, and very significant skin changes from major weight loss may not fully resolve without a surgical procedure. Understanding both sides of that honestly is more useful than a list of tips that quietly imply your skin will snap back like elastic if you just drink enough water.

Skin changes after significant weight loss vary widely. For personalized guidance, speak with your provider or a dermatologist.

Why Skin Behaves the Way It Does After Weight Loss

Skin is not passive tissue. Its firmness and elasticity depend on two structural proteins in the dermis: collagen, which provides tensile strength and structure, and elastin, which allows the skin to stretch and return to its original position. 

When skin has been stretched over a larger body for months or years, those proteins have adapted to that size. They don’t simply snap back when the volume beneath them decreases.

The degree to which skin can rebound depends on several factors: how long it was stretched, how much weight was lost, the speed of the loss, age, genetics, sun exposure history, and whether the person smokes. Some of these factors are out of your control. Others are directly influenced by how you approach weight loss and what you do during the process.

The Rate of Loss: Why It Matters More Than Most People Realize

This is one of the most actionable pieces of the loose skin conversation, and it’s frequently underemphasized.

Rapid weight loss gives skin very little time to adapt. When the underlying fat volume decreases quickly, the skin has not had an opportunity to gradually remodel its collagen structure. 

The result is a larger gap between skin surface area and underlying tissue. Slower weight loss allows the dermal layer more time to contract and rebuild, which tends to produce better skin outcomes even when the total amount of weight lost is the same.

This is one of the less obvious arguments for medically supervised weight loss over crash dieting. A clinically guided program that manages the pace of loss with an appropriate caloric approach and regular monitoring creates more favorable conditions for skin remodeling than a highly aggressive deficit that takes weight off as fast as possible. 

If you’re on a GLP-1 program through Precision Telemed, the structured titration built into compounded semaglutide or compounded tirzepatide protocols helps moderate the pace of loss, which is relevant to skin health in addition to tolerability.

Protein: Building Blocks That Skin Actually Needs

Collagen is a protein. Producing and maintaining it requires an adequate supply of amino acids from dietary protein. When caloric intake drops significantly, the body can prioritize energy needs over collagen maintenance if protein intake is insufficient.

For people losing weight through GLP-1 therapy or other approaches that reduce appetite, there’s a real risk of eating too little protein without being aware of it. The appetite suppression that makes these medications effective also makes it easy to undereat across the board. 

Prioritizing protein intake by leaning on foods like eggs, Greek yogurt, chicken, fish, legumes, and cottage cheese supports both the preservation of lean muscle and the structural integrity of the skin during weight loss.

Adequate protein doesn’t guarantee skin elasticity, but insufficient protein will work against it.

Resistance Training and the Skin

Building muscle beneath loose skin creates a firmer surface underneath. That’s the commonly cited reason to lift weights during a weight loss period, and it’s valid. But newer research suggests resistance training’s effects on skin go beyond simply filling space with muscle.

A 2023 study published in Scientific Reports examined the effects of both aerobic and resistance training on skin aging markers in sedentary middle-aged women over 16 weeks. Both types of training improved skin elasticity and upper dermal structure. 

Only the resistance training group, however, also showed an increase in dermal thickness. The researchers identified changes in circulating inflammatory factors and enhanced expression of extracellular matrix genes in dermal fibroblasts as part of the mechanism.

In practical terms: resistance training appears to benefit the skin directly, not just indirectly through body composition. That’s a meaningful finding for anyone losing weight who wants to support their skin’s structural integrity, not just its appearance.

Two to three sessions per week of compound movements (squats, deadlifts, rows, presses) provide a good foundation. The goal isn’t maximum aesthetics during the process; it’s preserving and building lean tissue while the fat comes off.

Nutrients With Meaningful Evidence

Beyond protein and exercise, a few specific nutrients have research backing that goes beyond general wellness advice.

Vitamin C is a required cofactor for collagen synthesis. Without sufficient vitamin C, the body cannot produce collagen normally. Most people eating a varied diet get enough, but those on very restricted calorie plans or following narrow elimination diets may fall short. Citrus fruit, bell peppers, strawberries, and leafy greens are reliable sources.

Collagen peptides (hydrolyzed collagen) have been studied in controlled trials for their effects on skin elasticity. A systematic review published in the International Journal of Dermatology found that oral collagen supplementation produced measurable improvements in skin hydration, elasticity, and density across multiple trials. The evidence is not definitive enough to call collagen supplementation essential, but it is reasonable enough to include if the rest of the nutritional foundation is solid.

Zinc plays a role in collagen synthesis and wound healing, and mild deficiency is more common than most people expect. Dietary sources include meat, shellfish, legumes, and nuts.

Hydration matters too, though its impact is often overstated. Skin hydration is one factor in maintaining elasticity, not the main driver, but a relevant one, particularly for people exercising regularly.

What May Not Fully Resolve on Its Own

This part deserves honesty.

When very large amounts of weight are lost, especially after years of carrying that weight, the degree of skin stretching may exceed what any combination of nutrition, exercise, and time can fully address. In these cases, the structural changes in the skin’s collagen network are significant enough that lifestyle strategies alone cannot produce complete resolution.

Body contouring and panniculectomy procedures are legitimate medical options in these situations. They’re not cosmetic vanity; for many people who have achieved significant weight loss, excess skin causes physical discomfort, hygiene issues, and limits physical activity. 

The appropriate response to this reality is not discouragement. Losing the weight is still worth it, regardless of what the skin does afterward. The health improvements from significant weight loss are real and meaningful. Skin concerns, while valid, do not change that calculus.

Growth Hormone, Skin Quality, and Personalized Programs

One factor in skin thickness and collagen production that receives less attention in general weight loss discussions is growth hormone. Growth hormone plays a direct role in collagen synthesis and skin quality. 

Natural production declines with age, which is part of why skin tends to be more resilient in younger people losing weight than in older adults.

For patients in appropriate clinical contexts, sermorelin therapy is a growth hormone secretagogue that stimulates the pituitary gland to produce more growth hormone naturally. While it’s not a treatment specifically for loose skin, its broader effects on body composition and collagen production make it a relevant consideration in the context of a comprehensive program.

The most effective approach to supporting your skin during weight loss is not a single supplement or tip. It’s a combination of managing loss pace, eating enough protein, training with resistance, and staying consistent over time. 

Working with a medical team that can oversee all of those elements together gives you a better shot at the outcomes you’re hoping for. 

You can learn more about Precision Telemed‘s personalized weight loss programs and get started!

Skin changes after significant weight loss vary widely. For personalized guidance, speak with your provider or a dermatologist. This content is for informational purposes only and does not constitute medical advice.

It’s one of the questions people hesitate to bring up at appointments, even though it comes up constantly in private conversations and online communities: has semaglutide changed my period?

The honest answer is: for some women, yes. And whether that change is something to welcome, something to watch, or something to address with a provider depends entirely on the individual. This article is meant to give you the context to tell the difference.

Menstrual changes during treatment should be discussed with your healthcare provider. Semaglutide is not a contraceptive. If you are pregnant or planning to become pregnant, consult your provider immediately as GLP-1 agonists are not recommended during pregnancy.

What Women Are Actually Reporting

Menstrual changes on semaglutide have not been systematically studied in large clinical trials the way weight loss outcomes have. What exists is a meaningful body of anecdotal reports, along with some smaller studies focused on specific populations, particularly women with PCOS.

The types of changes women report vary. Some notice cycles becoming irregular, heavier, or lighter than usual. Others, particularly those who had unpredictable cycles before starting treatment, report the opposite: more regularity and predictability than they’d had in years. A smaller number report temporary changes in timing, especially during periods of rapid weight loss.

None of these experiences is universal, and none should be dismissed as coincidental. Menstrual cycles are sensitive to metabolic shifts, and semaglutide produces real metabolic changes. It would be more surprising if there were no hormonal ripple effects at all.

Why Semaglutide Might Affect Your Cycle

The connection between body weight, insulin sensitivity, and reproductive hormones is well established. Adipose tissue is hormonally active; it produces and stores estrogen, and significant changes in fat mass can alter circulating hormone levels. When someone loses weight relatively quickly, especially in the early months of treatment, the hormonal environment changes along with body composition.

This matters for the menstrual cycle because the hypothalamic-pituitary-ovarian axis (the hormonal feedback loop that regulates ovulation and menstruation) responds to these shifts. 

During periods of rapid weight loss, the body can interpret the energy deficit as metabolic stress, which may temporarily disrupt cycle timing or flow. This is not unique to semaglutide; the same phenomenon has been documented in other contexts of significant caloric deficit or rapid weight change.

Beyond the weight loss mechanism, semaglutide also improves insulin sensitivity directly. In women with underlying insulin resistance, this can have meaningful downstream effects on sex hormone regulation, often in ways that are clinically beneficial.

The PCOS Connection: When a Changed Period Is Good News

For women with polycystic ovary syndrome, menstrual changes on semaglutide may actually represent progress.

PCOS is deeply tied to insulin resistance and weight. Elevated insulin levels drive excess androgen production, which suppresses normal ovulation and contributes to the irregular cycles that characterize the condition. When insulin resistance improves and body weight decreases, that androgen excess can diminish, and regular ovulation may return, sometimes for the first time in years.

A 2023 study published in the Journal of Clinical Medicine looked at 27 obese women with PCOS who had not responded to lifestyle modification programs. After six months of semaglutide treatment, 80% of those who achieved meaningful weight loss also showed normalization of their menstrual cycles. 

Those results were obtained alongside improvements in fasting glucose, insulin levels, and BMI, a cluster of changes that reflect what happens when the underlying metabolic dysfunction driving PCOS is finally addressed.

For women with PCOS specifically, a newly regular or more predictable cycle can signal that the hormonal environment is improving. It’s worth discussing with your provider rather than treating as an incidental development.

We’ve also written about how GLP-1 receptor agonists affect PCOS in the context of tirzepatide, which shares a similar metabolic mechanism through GIP and GLP-1 receptor activation.

When a Changed Period Warrants a Closer Look

Not every menstrual change on semaglutide has a straightforward positive interpretation. There are situations where changes in your cycle are worth a more thorough conversation with your provider.

If your periods become significantly heavier than usual, or if you experience pain that wasn’t present before, that’s worth evaluating. The same applies to any cycle change that coincides with other new symptoms: unusual fatigue, changes in thyroid function indicators, or unexpected hormonal symptoms that feel out of proportion to what might be explained by weight loss alone.

Irregular cycles in women who don’t have PCOS and weren’t experiencing irregularity before treatment should also prompt a conversation. While temporary disruption is possible during periods of rapid weight change, ongoing irregularity without a clear explanation deserves investigation rather than a waiting approach.

If you have a history of thyroid conditions, are taking hormonal medications, or have other conditions that affect your cycle, discussing semaglutide’s potential interactions in your specific situation is worth doing proactively rather than reactively. 

The compounded semaglutide program we offer at Precision Telemed includes ongoing provider access precisely for moments like this, when something changes and you want to understand what it means.

An Important Note on Fertility and Contraception

This section deserves particular attention, because it carries real practical consequences.

Semaglutide is not a contraceptive. It has no pregnancy-prevention effect. If anything, for women with conditions like PCOS where anovulation was previously limiting fertility, semaglutide may increase the likelihood of ovulation as metabolic function improves. A woman who had been told she was unlikely to conceive without intervention may find that changes as she loses weight on treatment.

If you are not trying to become pregnant, this means contraception is an active consideration during treatment, not something to defer until you notice a change. This is a conversation worth having with your prescribing provider early in your treatment course.

If you are trying to become pregnant, GLP-1 receptor agonists including semaglutide are not currently recommended during pregnancy, and standard guidance calls for discontinuation before attempting conception. Current recommendations suggest stopping semaglutide at least two months before trying to conceive to allow sufficient washout time. Your provider can walk you through the specific timing based on your individual situation.

And if you discover you are pregnant while taking semaglutide, contact your provider immediately. This is not cause for alarm, but it is a reason to act quickly and get appropriate guidance.

Periodic hormone and metabolic monitoring is available through lab work at Precision Telemed for patients who want to track how their hormonal markers are shifting alongside their weight and metabolic health throughout treatment.

Putting It Together

Semaglutide can affect your period. The change most commonly reported in women without underlying cycle disorders is a temporary disruption during significant weight loss, which tends to settle as weight stabilizes. For women with PCOS, the effects may be more meaningfully positive, reflecting improved hormonal regulation as insulin resistance decreases.

What a specific change means for you depends on your health history, your reproductive goals, and the full picture of what else is shifting in your body during treatment. That’s not a conversation that fits into a search result, but it is one that fits well into a telehealth visit.

Questions about your cycle, your fertility, or anything else your body is doing during treatment are exactly what follow-up telehealth visits are for. Nothing is too sensitive or too small to bring up. If you’d like to talk through what you’re experiencing with a Precision Telemed provider, you can get started today!

Menstrual changes during treatment should be discussed with your healthcare provider. Semaglutide is not a contraceptive. If you are pregnant or planning to become pregnant, consult your provider immediately as GLP-1 agonists are not recommended during pregnancy. This content is for informational purposes only and does not constitute medical advice.

You’ve done it. The first injection is behind you, and now comes the part no one talks about much: the waiting, the wondering, the quiet scan of every sensation to figure out if it’s the medication or just your body being its normal unpredictable self.

That experience is completely normal. And most people find that the first week is far more manageable than they expected, for reasons that have everything to do with how the dose escalation protocol was designed.

Here’s what you can reasonably expect over the next seven days, what’s worth tracking, and what would actually warrant a call to your provider.

If you experience any concerning symptoms after your first injection, contact your prescribing provider or seek medical care promptly.

Why the First Week Is Usually Gentler Than You Might Expect

Semaglutide is started at a low introductory dose before gradually increasing over several months to a therapeutic maintenance dose. This ramp-up is intentional. Prescribing guidelines build in this escalation precisely because starting lower reduces the likelihood of significant side effects while your body adjusts to the medication.

For many people, the first two to four weeks on semaglutide are the mildest of the entire treatment period. The dose at this stage is below the level at which most people experience the appetite effects the medication is known for. You may notice subtle changes, but pronounced effects are not typical this early.

That said, your body is still responding to something new. Knowing what to watch for helps you distinguish between normal adjustment and something that needs attention.

The First 24 to 48 Hours

Injection site reactions are the most common experience in the first day or two. A small area of redness, mild tenderness, or slight swelling right where you injected is typical and usually resolves within 24 hours. Rotating your injection site, letting the medication reach room temperature before injecting, and using a slow, steady technique can all reduce discomfort.

Some people notice a mild reduction in appetite within the first 24 hours. For others, there’s no discernible appetite change this early. Both experiences are normal.

Nausea is the side effect people most often ask about, and it’s worth being straightforward: some people do experience mild nausea in the first day or two, particularly in the hours after injection. 

At the starting dose, it tends to be brief. Eating smaller portions, avoiding heavy or fatty foods around injection time, and staying well-hydrated are among the most effective ways to reduce it. Plain crackers, ginger tea, and smaller, protein-focused meals tend to be better tolerated during the adjustment window.

A small number of people experience mild fatigue or a light headache in the first 24 to 48 hours. These also tend to pass quickly.

Days 3 Through 7

By the middle of the first week, most people have settled into a fairly ordinary routine. Any injection site reaction has resolved. Whatever nausea appeared in the first day or two has typically eased.

What some people begin to notice around days four through seven is a quiet but real shift in their relationship with food. Portions that felt standard before may feel like more than enough. The pull of specific cravings may be noticeably less insistent. Not everyone experiences this at the starting dose, but when it happens, it’s one of the earliest signals that the medication is beginning to work as intended.

Gastrointestinal changes can appear during this window. Some people report looser stools, mild constipation, or a sense of fullness that arrives sooner than usual during meals. None of these are alarming on their own. They reflect how semaglutide slows gastric emptying and alters gut hormone signaling, which is part of the mechanism behind its weight loss effects. 

Spacing out meals, eating slowly, and keeping portions moderate all help during this adjustment period.

If fatigue was present earlier in the week, most people find it has improved by day four or five.

When to Contact Your Provider

Most first-week experiences with semaglutide fall well within the expected range. But certain symptoms are reasons to contact your prescribing provider promptly, and some warrant immediate medical care.

Contact your provider or seek care if you notice:

• Vomiting that is persistent or severe enough that you cannot keep fluids down
• Severe abdominal pain, particularly if it radiates to your back or is accompanied by fever
• Signs of an allergic reaction: facial swelling, swelling of the lips or throat, difficulty breathing, hives, or a rapid heartbeat

These symptoms are uncommon at the starting dose, but they are reasons to stop and get guidance rather than wait. The prescribing and safety information page on our site covers the medication’s safety profile in detail and is worth reading if you have not already.

Mild to moderate nausea, a brief bout of loose stools, or some injection-site redness are not reasons to stop the medication. They are the body adjusting to a new signal. But anything that feels disproportionate, severe, or extends more than a couple of days should be communicated to your provider.

Small Adjustments That Actually Help

A few practical changes can make the first week considerably more comfortable.

On injection days, consider eating lighter than usual, particularly for the meal closest to your injection time. Protein and fiber tend to sit better than heavy, fatty dishes. 

Carbonated beverages can worsen nausea for some people; plain water and ginger-based drinks are gentler. If nausea hits at a consistent time of day, try shifting when you inject so that the window of highest sensitivity doesn’t overlap with a large meal.

Some people find morning injections easier to manage; others prefer evenings. There is no universally right answer, and it may take a few weeks to find your rhythm.

Normal levels of physical activity are fine during the first week. Unless your provider has advised otherwise, you do not need to modify your exercise routine based on the medication alone.

What Comes Next: After Week One

Once the first week passes, the pattern of each subsequent month becomes more predictable. Your dose will be evaluated for potential escalation at regular intervals, and each new dose level may bring a brief re-adjustment period that can resemble what you experienced in week one, though often milder as your body becomes more familiar with the medication.

The STEP-1 trial published in the New England Journal of Medicine found that GI adverse events were most frequent during the dose escalation phase and declined in prevalence over time as participants reached and maintained their therapeutic dose. For the majority of participants who stayed in the trial, side effects became less disruptive as treatment continued.

Staying in regular contact with your provider throughout this process makes a real difference in both comfort and outcomes. Follow-up visits, which at Precision Telemed are conducted via telehealth, give you a structured opportunity to discuss what you’re experiencing, review your progress, and make any adjustments to your protocol. 

Depending on your program, periodic lab work may also be part of your care plan to track how your metabolic markers are responding as your treatment progresses.

If you want to read more about the compounded semaglutide program at Precision Telemed, including dosing structure and what’s included in your care, that information is available on our service page.

A Note on What Normal Progress Actually Looks Like

It’s tempting to spend the first week looking for dramatic proof that the medication is working. The reality is that the starting phase is quiet by design. Significant weight loss is not the first-week goal. The goal in week one is simply tolerating the medication well, establishing a routine, and beginning to build the foundation for the months ahead.

Progress with semaglutide is measured in months, not days. The first injection is one small step in a longer, medically supervised process. If week one was unremarkable, that is a good thing.

If you have questions about what you’re experiencing or would like to schedule a follow-up telehealth visit to check in on your progress, Precision Telemed providers are available to walk through it with you. Connect with a provider today!

If you experience any concerning symptoms after your first injection, contact your prescribing provider or seek medical care promptly. This content is for informational purposes only and does not constitute medical advice.

Spend enough time researching weight loss medications and you’ll run into the phrase “metabolism booster” eventually. It appears in supplement ads, wellness blogs, and, increasingly, in conversations about GLP-1 drugs. 

The claim is seductive because it promises something most people deeply want: a body that burns calories more readily, not just one that’s been put on a strict intake ceiling.

Tirzepatide deserves a more careful answer than most treatments get on this topic. Not because the hype is accurate, but because the underlying science is genuinely interesting. 

Yes, tirzepatide does appear to have meaningful effects on how the body handles energy. No, those effects are not what the word “boost” typically implies. Understanding the difference matters for anyone considering this medication or trying to interpret what they’re experiencing while taking it.

This article summarizes clinical research findings. Individual metabolic responses vary.

What Happens to Metabolism When You Lose Weight the Traditional Way

Any honest conversation about tirzepatide’s metabolic effects has to start with what happens to metabolism during conventional weight loss, because that context is the whole reason the question matters.

When calorie intake drops significantly and body weight falls, resting metabolic rate declines. Part of that decline is expected. A smaller body requires fewer calories to sustain itself, so some reduction in energy expenditure is simply proportional to the weight lost. 

The harder part to contend with is a secondary phenomenon researchers call metabolic adaptation: the body burning fewer calories than the weight loss itself would predict.

This adaptive slowing appears to be the body’s response to perceived energy scarcity. It conserves fuel. And it can persist for years after the weight loss occurs, which is one of the reasons people who lose large amounts of weight through diet alone often struggle to maintain it. The physiological environment has shifted in ways that favor regain.

This is the backdrop against which tirzepatide’s mechanism becomes worth examining carefully.

How Tirzepatide’s Dual Mechanism Relates to Metabolism

Tirzepatide is a dual agonist: it activates both the GLP-1 and GIP receptors simultaneously. For people more familiar with semaglutide, GLP-1 agonism is the familiar part: it reduces appetite, slows gastric emptying, and influences hunger-regulating pathways in the brain. 

The GIP component is what makes tirzepatide pharmacologically distinct from older GLP-1 medications, and it’s where much of the metabolic interest lies. 

Our compounded tirzepatide page has a fuller breakdown of how this dual mechanism works clinically.

GIP receptors are found not just in the gut but in adipose tissue and skeletal muscle. This distribution gives GIP agonism pathways to influence how fat cells store and release energy, and how efficiently the body shifts between fuel sources. 

When both receptors are activated together, the downstream effects on energy metabolism appear to be greater than what either agonist produces alone, a finding that has been a consistent theme across the SURMOUNT clinical trial program.

What the Clinical Research Actually Found

A 2024 study published in Cell Metabolism looked directly at tirzepatide’s effects on energy expenditure, fat oxidation, and macronutrient utilization in both preclinical models and a phase 1 human trial. The findings drew a more nuanced picture than a simple yes or no answer would allow.

In calorie-restricted obese mice, tirzepatide reduced the drop in energy expenditure that occurred in vehicle-treated animals, suggesting the drug may attenuate metabolic adaptation under those conditions. In the human arm of the study, the results were different: tirzepatide did not appear to significantly prevent the metabolic adaptation that comes with weight loss. 

What it did produce, clearly, was a meaningful increase in fat oxidation. The respiratory quotient (a measure of what fuel the body is burning) shifted toward greater reliance on fat. Reductions in appetite and calorie consumption during test meals were also observed relative to placebo.

That fat oxidation finding is clinically meaningful. It suggests tirzepatide is influencing how the body allocates its fuel, not merely creating a calorie deficit through appetite suppression alone. The SURMOUNT-1 trial, which tested tirzepatide in adults with obesity without diabetes, demonstrated up to 20.9% mean body weight reduction at 72 weeks with the 15mg dose. 

Importantly, body composition data showed a higher proportion of fat mass lost relative to lean mass compared to what calorie restriction alone typically produces, a pattern consistent with the fat oxidation shift identified in the mechanistic research.

Body Composition: Why the Type of Weight Lost Matters

This is one of the more practical and underappreciated aspects of tirzepatide’s metabolic profile. Total weight lost is one metric. Where that weight comes from is a different question entirely.

Lean mass, skeletal muscle primarily, is metabolically active. It contributes directly to resting metabolic rate. When the body loses weight but sheds a high proportion of lean mass in the process, the metabolic consequences can be significant. Resting energy expenditure drops, functional strength declines, and the conditions for weight regain become more favorable.

Tirzepatide’s tendency to produce fat-preferential weight loss, when paired with adequate protein intake and resistance exercise, creates a more favorable environment for preserving that metabolically active tissue. 

This doesn’t mean muscle loss is impossible on tirzepatide (it isn’t, and caloric deficit always carries some lean mass risk), but the mechanism appears to create better conditions than calorie restriction alone. Patients interested in how peptide therapy intersects with body composition and recovery often find sermorelin worth discussing with their provider as a complementary option, particularly for those concerned about lean mass preservation.

Insulin Sensitivity and the Restoration of Normal Signaling

Obesity frequently impairs insulin sensitivity. Cells become less responsive to insulin’s signals, which disrupts glucose uptake, promotes fat storage, and creates a metabolic feedback loop that makes both weight loss and weight maintenance harder. This disrupted signaling is part of why obesity functions as a chronic disease rather than simply a matter of intake versus expenditure.

Tirzepatide, particularly through its GIP agonism, has demonstrated improvements in insulin sensitivity that appear to go beyond what weight loss alone would produce. Restoring that sensitivity doesn’t just help blood glucose regulation; it helps restore the normal metabolic environment in which the body is supposed to be operating.

This framing is the most scientifically accurate way to understand what tirzepatide does to metabolism. It’s not supercharging a healthy system. It’s working to correct disrupted signaling that obesity has impaired over time. That’s a fundamentally different thing, and it sets more grounded expectations about what the medication can and can’t do.

For those interested in the broader picture of metabolic health, our piece on GLP-1 therapy and NAD+ explores how cellular energy metabolism and these signaling pathways intersect in ways that go beyond weight alone.

Putting It Together

Does tirzepatide increase metabolism? Tirzepatide doesn’t “speed up” your metabolism like a stimulant. It doesn’t artificially increase calorie burning or create the jittery effects associated with fat burners.

What it actually does is help your body function more efficiently metabolically. It improves insulin sensitivity, reduces appetite, encourages the body to use fat for energy, and helps preserve muscle during weight loss.

So while it may support a healthier metabolism, it’s not a traditional “metabolism booster.”

The best way to understand whether tirzepatide’s metabolic effects are a good fit for your specific health picture (your labs, your body composition, your history) is to talk through it with a provider who can look at your individual data. If you’re ready to have that conversation, you can connect with a Precision Telemed provider!

This article summarizes clinical research findings. Individual metabolic responses vary. This content does not constitute medical advice and is not a substitute for consultation with a licensed healthcare provider.